Last reviewed · How we verify
IM96 CAR-T Cells
At a glance
| Generic name | IM96 CAR-T Cells |
|---|---|
| Sponsor | Beijing Immunochina Medical Science & Technology Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction (PHASE1)
- Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer (PHASE1)
- Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IM96 CAR-T Cells CI brief — competitive landscape report
- IM96 CAR-T Cells updates RSS · CI watch RSS
- Beijing Immunochina Medical Science & Technology Co., Ltd. portfolio CI